(-0.38%) 5 016.66 points
(0.18%) 37 882 points
(-0.47%) 15 584 points
(-2.80%) $79.64
(-3.52%) $1.921
(0.57%) $2 316.10
(0.12%) $26.69
(1.64%) $963.75
(-0.05%) $0.937
(-0.15%) $11.08
(0.08%) $0.801
(-0.05%) $93.40
Live Chart Being Loaded With Signals
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide...
Stats | |
---|---|
Šios dienos apimtis | 5.63M |
Vidutinė apimtis | 686 607 |
Rinkos kapitalizacija | 1.49B |
EPS | $0 ( 2023-05-04 ) |
Last Dividend | $0.125 ( 2019-02-01 ) |
Next Dividend | $0 ( N/A ) |
P/E | 21.09 |
ATR14 | $0.299 (0.88%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-01-31 | Williams Felicia | Sell | 10 274 | Common Stock |
2023-01-31 | Williams Felicia | Sell | 12 000 | Stock Option (Right to Buy) |
2023-01-31 | Williams Felicia | Sell | 8 740 | Stock Option (Right to Buy) |
2023-01-31 | Williams Felicia | Sell | 17 205 | Stock Option (Right to Buy) |
2023-01-31 | Williams Felicia | Sell | 5 796 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-88.83 |
Last 100 transactions |
Buy: 118 571 | Sell: 1 534 678 |
Tūris Koreliacija
Meridian Bioscience Inc Koreliacija
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Meridian Bioscience Inc Koreliacija - Valiuta/Žaliavos
Meridian Bioscience Inc Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $333.02M |
Bruto pelnas: | $188.36M (56.56 %) |
EPS: | $0.960 |
FY | 2022 |
Pajamos: | $333.02M |
Bruto pelnas: | $188.36M (56.56 %) |
EPS: | $0.960 |
FY | 2021 |
Pajamos: | $317.90M |
Bruto pelnas: | $201.15M (63.27 %) |
EPS: | $1.650 |
FY | 2020 |
Pajamos: | $253.67M |
Bruto pelnas: | $156.25M (61.60 %) |
EPS: | $1.080 |
Financial Reports:
No articles found.
Meridian Bioscience Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.00678 | 1990-11-29 |
Last Dividend | $0.125 | 2019-02-01 |
Next Dividend | $0 | N/A |
Payout Date | 2019-02-14 | |
Next Payout Date | N/A | |
# dividends | 114 | -- |
Total Paid Out | $9.88 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.53 | -- |
Div. Sustainability Score | 0.950 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0.115 | -- |
Year | Amount | Yield |
---|---|---|
1990 | $0 | 0.00% |
1991 | $0 | 0.00% |
1992 | $0 | 0.00% |
1993 | $0 | 0.00% |
1994 | $0 | 0.00% |
1995 | $0 | 0.00% |
1996 | $0 | 0.00% |
1997 | $0 | 0.00% |
1998 | $0 | 0.00% |
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0.160 | 3.50% |
2004 | $0.178 | 3.83% |
2005 | $0.213 | 2.70% |
2006 | $0.307 | 2.09% |
2007 | $0.434 | 2.63% |
2008 | $0.560 | 1.88% |
2009 | $0.680 | 2.60% |
2010 | $0.760 | 3.51% |
2011 | $0.760 | 3.21% |
2012 | $0.950 | 4.98% |
2013 | $0.570 | 2.75% |
2014 | $0.800 | 3.06% |
2015 | $0.800 | 4.88% |
2016 | $0.800 | 4.10% |
2017 | $0.500 | 2.80% |
2018 | $0.500 | 3.47% |
2019 | $0.125 | 0.74% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.197 | 1.500 | -3.93 | -5.90 | [0 - 0.5] |
returnOnAssetsTTM | -0.0528 | 1.200 | -1.760 | -2.11 | [0 - 0.3] |
returnOnEquityTTM | -0.0681 | 1.500 | -1.867 | -2.80 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.56 | 0.800 | 2.18 | 1.741 | [1 - 3] |
quickRatioTTM | 1.472 | 0.800 | 6.05 | 4.84 | [0.8 - 2.5] |
cashRatioTTM | 0.943 | 1.500 | 5.87 | 8.81 | [0.2 - 2] |
debtRatioTTM | 0.0682 | -1.500 | 8.86 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -65.48 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.00825 | 2.00 | -0.00275 | -0.00550 | [0 - 30] |
freeCashFlowPerShareTTM | -0.148 | 2.00 | -0.0740 | -0.148 | [0 - 20] |
debtEquityRatioTTM | 0.0914 | -1.500 | 9.63 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.534 | 1.000 | 4.43 | 4.43 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.197 | 1.000 | -5.93 | -5.93 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.0116 | 1.000 | -1.176 | -1.176 | [0.2 - 2] |
assetTurnoverTTM | 0.268 | 0.800 | -1.544 | -1.235 | [0.5 - 2] |
Total Score | 0.950 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -61.83 | 1.000 | -6.35 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0681 | 2.50 | -1.200 | -2.80 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.148 | 2.00 | -0.0493 | -0.148 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.00825 | 2.00 | -0.00275 | -0.00550 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 1.518 | 1.500 | 3.22 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.00295 | 1.000 | -2.57 | 0 | [0.1 - 0.5] |
Total Score | -0.720 |
Meridian Bioscience Inc
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.